Page 2 - First Occurrence News Today

Message : Required fields Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Pati...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce ... Amarin Corporation plcMarch 17, 2021 GMT 28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients wi...

Share: 28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke re...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Amarin Corporation plcFebruary 25, 2021 GMT Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact Received Positive CHMP Opinion for VAZKEPA ® in Europe and Continue to Advance Commercial Launch Plans for Europe Management to Host Conference Call...

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

News Category Global Banking & Finance Reviews Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 — Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amarin Provides Preliminary 2020 Results and 2021 Outlook Amarin Corporation plcJanuary 7, 2021 GMT Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019 Completion of European Regulatory Review and Submission of China Regulatory Application for VASCEPA® (icosapent ethyl) Expected in Late January or February 2021 DUBLIN, Irela...

Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results December 14, 2020 05:00 ET | Source: Amarin Corporation plc Amarin Corporation plc Bedminster, New Jersey, UNITED STATES REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to...